A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic Plasmodium berghei Parasite

Protective Immunity in Mice Immunized With P. vivax MSP119-Based Formulations and Challenged With P. berghei Expressing PvMSP119

(2020) Irina Dobrescu et al.   Frontiers in Immunology

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein

(2020) Rodolfo F. Marques et al.   Vaccines

Malaria Vaccines: Recent Advances and New Horizons

(2018) Simon J. Draper et al.   Cell Host & Microbe

A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

(2018) Neville K Kisalu et al.   NATURE MEDICINE

Malaria vaccine: WHO position paper, January 2016 – Recommendations

(2018)   VACCINE

The Promise of a Malaria Vaccine—Are We Closer?

(2018) Matthew B. Laurens   Annual Review of Microbiology

Selection of immunodominant epitopes during antigen processing is hierarchical

(2018) Scheherazade Sadegh-Nasseri et al.   MOLECULAR IMMUNOLOGY

Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge

(2018) Tarsila Mendes de Camargo et al.   Scientific Reports

Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin

(2018) Eduardo Aliprandini et al.   Nature Microbiology

Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1 19

(2017) Mariana Vilela Rocha et al.   VACCINE

Immune Responses in Malaria

(2017) Carole A. Long et al.   Cold Spring Harbor Perspectives in Medicine

Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax

(2017) Anjali Yadava et al.   PLoS Neglected Tropical Diseases

Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite

(2017) Alba Marina Gimenez et al.   Frontiers in Immunology

What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?

(2017) Carolina López et al.   Frontiers in Immunology

Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models

(2017) Ahmed M. Salman et al.   Scientific Reports

Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara

(2016) Mahamadou A. Thera et al.   MALARIA JOURNAL

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity

(2016) Sidhartha Chaudhury et al.   MALARIA JOURNAL

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

(2016) Jason W. Bennett et al.   PLoS Neglected Tropical Diseases

Proteolytic Cleavage of thePlasmodium falciparumCircumsporozoite Protein Is a Target of Protective Antibodies

(2015) Diego A. Espinosa et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of Recombinant Proteins Consisting of Plasmodium vivax Circumsporozoite Protein Allelic Variant-Derived Epitopes Fused with Salmonella enterica Serovar Typhimurium Flagellin

(2013) Monica Teixeira Andrade Leal et al.   Clinical and Vaccine Immunology

Invasion-Inhibitory Antibodies Elicited by Immunization with Plasmodium vivax Apical Membrane Antigen-1 Expressed in Pichia pastoris Yeast

(2013) Elaine C. Vicentin et al.   INFECTION AND IMMUNITY

Development of a Chimeric Plasmodium berghei Strain Expressing the Repeat Region of the P. vivax Circumsporozoite Protein forIn VivoEvaluation of Vaccine Efficacy

(2013) Diego A. Espinosa et al.   INFECTION AND IMMUNITY

Immunogenicity of a Prime-Boost Vaccine Containing the Circumsporozoite Proteins of Plasmodium vivax in Rodents

(2013) Lais H. Teixeira et al.   INFECTION AND IMMUNITY

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

(2013) Ilin Chuang et al.   PLoS One

Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques

(2013) Yannick Vanloubbeeck et al.   VACCINE

Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

(2013) Cindy Tamminga et al.   Human Vaccines & Immunotherapeutics

Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I·C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+T Cell Immunity and Protection in Mice

(2012) Kathrin Kastenmüller et al.   INFECTION AND IMMUNITY

Human ex vivo studies on asexual Plasmodium vivax: The best way forward

(2012) Bruce Russell et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

Cross-Species Immunity Following Immunization With a Circumsporozoite Protein–Based Vaccine for Malaria

(2012) Anjali Yadava et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

(2012) Joanne M. Lumsden et al.   VACCINE

Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants

(2011) Myriam Arévalo-Herrera et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

(2011) Joanne M. Lumsden et al.   INFECTION AND IMMUNITY

TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium

(2011) Ariane Guglielmi Ariza Camacho et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

(2011) Cindy Tamminga et al.   PLoS One

Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood

(2009) Kanlaya Sriprawat et al.   MALARIA JOURNAL

Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A

(2009) Michele D. Spring et al.   PLoS One

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

(2009) Issaka Sagara et al.   VACCINE

Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax

(2009) Brian A. Bell et al.   VACCINE

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

(2009) Issaka Sagara et al.   VACCINE

Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection

(2008) Bruno C. Múfalo et al.   MICROBES AND INFECTION

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity

(2008) Silayuv E. Bongfen et al.   VACCINE